Stefan Strobel - Marizyme Head Europe

All Insiders . USA . 
Stock . Marizyme . Stakeholders . Insider . Stefan Strobel
MRZM Stock  USD 0.05  0.01  25.00%   

Insider

Stefan Strobel is Head Europe of Marizyme
Phone561 935 9955
Webhttps://marizyme.com

Marizyme Management Efficiency

The company has return on total asset (ROA) of (0.1468) % which means that it has lost $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4956) %, meaning that it created substantial loss on money invested by shareholders. Marizyme's management efficiency ratios could be used to measure how well Marizyme manages its routine affairs as well as how well it operates its assets and liabilities.
Marizyme currently holds 495.32 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Marizyme has a current ratio of 1.71, which is within standard range for the sector. Debt can assist Marizyme until it has trouble settling it off, either with new capital or with free cash flow. So, Marizyme's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Marizyme sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Marizyme to invest in growth at high rates of return. When we think about Marizyme's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Erin ButlerArmata Pharmaceuticals
N/A
Benjamin DakeAerovate Therapeutics
48
Annie MackAkari Therapeutics PLC
N/A
Joseph CPAInhibikase Therapeutics
62
BSc FRCPCInhibikase Therapeutics
N/A
MBA MRAerovate Therapeutics
62
RAC SakaiTempest Therapeutics
N/A
Roger RushInhibikase Therapeutics
N/A
Duane BAArmata Pharmaceuticals
74
Dan WilliamsInhibikase Therapeutics
N/A
Miles NunnAkari Therapeutics PLC
55
Robert FloydProcessa Pharmaceuticals
68
PharmD BigoraProcessa Pharmaceuticals
64
George EldridgeAerovate Therapeutics
61
Timothy PigotAerovate Therapeutics
53
Timothy MBAAerovate Therapeutics
62
Justin TrojanowskiTempest Therapeutics
36
Steven MartinArmata Pharmaceuticals
63
Scott AndersonAnebulo Pharmaceuticals
N/A
Torsten HombeckAkari Therapeutics PLC
54
Melissa BradfordKlugAkari Therapeutics PLC
54
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people. Marizyme [MRZM] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-0.5
Return On Asset-0.15

Marizyme Leadership Team

Elected by the shareholders, the Marizyme's board of directors comprises two types of representatives: Marizyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Marizyme. The board's role is to monitor Marizyme's management team and ensure that shareholders' interests are well served. Marizyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Marizyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kari Jacobson, Controller
Stefan Strobel, Head Europe
George CPA, CFO Treasurer
Claudio MD, Chief Logic
Harrison CFA, VP Fin
David MBA, S CEO
FACC MBA, Ex Officer
Catherine Pachuk, Ex Officer

Marizyme Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Marizyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.5
Return On Asset-0.15
Operating Margin(180.85) %
Current Valuation17.35 M
Shares Outstanding10.13 M
Shares Owned By Insiders2.04 %
Price To Book0.37 X
Price To Sales133.06 X
Revenue210.28 K
Gross Profit129.93 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Marizyme OTC Stock

Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY